Peer-reviewed veterinary case report
Safe and effective tumor injection treatment for dog mast cell tumors
By De Ridder, Thomas R et al.·Published in Journal of veterinary internal medicine·2021·QBiotics Group Limited, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).
- Species:
- dog
Plain-English summary
A group of 123 dogs with diagnosed mast cell tumors (MCTs) received a new treatment called tigilanol tiglate, injected directly into their tumors. After 28 days, 75% of the dogs showed complete tumor resolution, and by 84 days, 93% of those dogs had no recurrence. Even some dogs that initially didn't respond to the treatment were able to achieve complete resolution after a second dose, bringing the overall success rate to 88%. The treatment was generally well tolerated, with only mild side effects noted. This offers a promising new option for treating mast cell tumors in dogs.
People also search for: dog mast cell tumor treatment · tigilanol tiglate for dogs · mast cell tumor recovery in dogs
Abstract
OBJECTIVE: To evaluate the efficacy and safety of tigilanol tiglate (TT) for local intratumoral treatment of mast cell tumors (MCTs) in dogs. METHODS: A randomized controlled clinical study in 2 phases involving 123 dogs with cytologically diagnosed MCT. Phase 1 compared 81 TT-treated dogs with 42 control dogs; phase 2 allowed TT treatment of control dogs and retreatment of dogs that failed to achieve tumor resolution after TT treatment in phase 1. Tigilanol tiglate (1 mg/mL) was injected intratumorally with dose based on tumor volume. Concomitant medications were used to minimize potential for MCT degranulation. Modified response evaluation criteria in solid tumors were used to evaluate treatment response at 28 and 84 days. Adverse events and quality of life were also assessed. RESULTS: A single TT treatment resulted in 75% complete response (CR) (95% confidence interval [CI] = 61-86) by 28 days, with no recurrence in 93% (95% CI = 82-97) of dogs by 84 days. Eight TT-treated dogs that did not achieve CR in phase 1 achieved CR after retreatment, increasing the overall CR to 88% (95% CI = 77-93). Control dogs had 5% CR (95% CI = 1-17) at 28 days. Wound formation after tumor slough and wound size relative to tumor volume were strongly associated with efficacy. Adverse events typically were low grade, transient, and directly associated with TT's mode of action. CONCLUSIONS: Tigilanol tiglate is efficacious and well tolerated, providing a new option for the local treatment of MCTs in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32542733/